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”Ja, livet är riskabelt nog min prins 
-törhända det riskablaste som finns. 
Men står man bara stark och håller ut 
får också denna farlighet sitt slut!” 
 
Lennart Hellsing ur ”Fem prinsar” 
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ABSTRACT
 
 
Colorectal cancer (CRC) is the second most common form of cancer in Europe, and population based 
screening for colorectal cancer is recommended by the European Union. Screening enables detection of 
precursor lesions, i.e. adenomas, and cancer at an early stage, and randomised trials have demonstrated 
that screening reduces mortality in colorectal cancer. In rectal cancer, oncological results after abdominal 
resection surgery have improved over many years, but the morbidity, mortality and negative functional 
side effects following surgery and oncological treatment are considerable. Local excision techniques, on 
the other hand, demonstrate excellent functional results and a low morbidity and mortality but have high 
local recurrence rates, mainly since the technique does not allow for excision of mesorectal lymph nodes, 
which could be exposed to metastatic disease not detectable in the preoperative radiological staging. 
Since further expansion of population based screening programs for CRC will increase the detection of 
early cancer, local excision techniques are of great interest, provided that an adequate oncological out-
come can be ensured. 
 
In paper I all patients in Sweden undergoing surgery for stage I rectal cancer 1995-2006 were assessed 
regarding survival, local recurrence rates and risk factors for death. Patients undergoing local excision 
had a higher local recurrence rate and a poor survival, especially in the age group ≥ 80 years, compared 
to patients undergoing abdominal resection surgery. 
 
Paper II analysed risk factors for lymph node metastases in patients with rectal cancer. All patients in 
Sweden 2007-2010 with histopathologically confirmed radical resections of pT1-2 rectal cancer follow-
ing abdominal resection surgery without (neo)adjuvant treatment were included. T2 stage, poor differen-
tiation and vascular infiltration were identified as risk factors for lymph node metastases. A model calcu-
lating the total risk depending on the number of risk factors included, displayed a risk range of 6-65 % 
and 11-78 % in T1 and T2 tumours respectively.  
 
In paper III all Swedish patients aged 60-69 years with screening detected colorectal cancer were com-
pared to those with non-screening detected cancer diagnosed 2008-2012. Pre- and postoperative staging, 
MDT-assessment, surgical and oncological treatment were compared between the groups. Patients with 
screening detected cancer were staged and MDT-assessed to a higher extent compared to those with non-
screening detected cancer and tumours were found at an earlier stage in the screening group. Surgical 
and oncological treatment did not differ between the groups. Patients with endoscopically resected can-
cer did not undergo staging and MDT-assessment to the same extent as did patients with surgically re-
sected cancer. 
 
Paper IV included all individuals with a positive FOBT in the Stockholm screening programme, January 
2008 - June 2012. Complications and mortality within 30 days after interventions, i.e. colonoscopies or 
surgery for adenomas or cancer, subsequent to a positive screening test were assessed. Total complica-
tion rates were acceptable and mortality was low, but the rate of anastomotic leakage, which was 13 % 
and 12 % in the adenoma and cancer surgery groups respectively, was higher than expected. 
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THESIS AT A GLANCE
 
 Paper I Paper II Paper III Paper IV 
Aim Comparison of long- 
term survival in pa-
tients with stage I rectal 
cancer after local exci-
sion vs. abdominal 
resection surgery. 
Assessment of risk fac-
tors for lymph node 
metastases in T1 and T2 
rectal cancer. 
Comparison of 
patients with screen-
ing detected vs. non-
screening detected 
CRC regarding 
staging, MDT-
assessment and 
treatment. 
Assessment of com-
plications and mortal-
ity after colonoscopy 
and surgery following  
a positive FOBT in 
screening individuals. 
Patients  All patients in Sweden 
undergoing surgery for 
stage I rectal cancer, 
1995-2006. 
All patients in Sweden 
undergoing abdominal 
surgery for rectal cancer, 
2007-2010, without 
(neo)adjuvant treatment. 
p T1-2 tumours includ-
ed. 
All patients in Swe-
den, 60-69 years 
old, with screening 
and non-screening 
detected CRC, 
2008-2012. 
All patients in the 
Stockholm/Gotland 
screening programme 
with a positive FOBT 
January 2008 - June 
2012. 
 
Methods  5-year survival and HR 
for mortality within 5 
years after surgery.  
Multivariate logistic 
regression analyses of 
the risk of lymph node 
metastases. 
Comparison of 
differences between 
the groups 
Assessment of 30-day 
mortality and compli-
cation rates. 
Results 5-year elative survival: 
anterior resection, 0.95 
(0.92-0.97), local exci-
sion 0.81 (0.75-0.88). 
Risk factors for 5-year 
mortality in patients  
 ≥ 80 years: 
Local excision, HR= 
1.55 (1.17-2.05), male 
gender HR= 1.59 (1.27-
1.99) and age HR= 
1.07 (1.04-1.11). 
T2 tumour stage,      
OR= 1.97 (1.19-3.25), 
poor differentiation, 
OR= 6.47 (2.71-15.4), 
vascular infiltration, 
OR= 4.34 (2.46-7.65). 
 
Staging of surgical-
ly resected tumour 
in screening (94 %) 
vs. non-screening 
(87 %) and of endo-
scopically resected 
tumour in screening 
(46 %) vs. non-
screening (24 %) 
groups. Correspond-
ing numbers for 
MDT assessment 
were 90 %, 69 %, 
25 % and 16 % 
respectively. 
Rates of post-
polypectomy bleeding 
14/1000 and perfora-
tion 2.5/1000. Com-
plication and anasto-
motic leakage rates 
after adenoma sur-
gery were 27 % and 
13 % respectively and 
after cancer surgery, 
50 % and 12 % re-
spectively. 
Conclusion The 5-year survival 
was poor after local 
excision surgery, espe-
cially in patients   ≥ 80 
years. 
T2 tumour stage, poor 
differentiation and vas-
cular infiltration were 
risk factors for lymph 
node metastases.  
Patients with 
screening detected 
CRC were exten-
sively staged and 
MDT assessed, but 
this was not the case 
for patients with 
endoscopically 
resected CRC. 
Overall complication 
rates and mortality 
were acceptable. 
Anastomotic leakage 
rates were higher than 
expected. 
11 
 
Deborah Saraste 
   
 
 
 
 
  
12 
LIST OF ABBREVIATIONS
 
 
ACG 
AJCC 
APE 
AR 
ASA  
                                                        
cCR 
CME 
CRC 
CRM 
CRT 
CT 
EMR 
ESD 
EUS 
FIT 
gFOBT 
Gy 
HR 
ICD-10 
IPR 
LE 
MDT 
MRI 
OR 
pCR 
SCRCR 
TA 
TEMS 
TME 
TNM 
UICC 
 
 
 
 
American College of Gastroenterology 
American Joint Committee for Cancer 
Abdominoperineal excision 
Anterior resection 
American Society of Anaseshesiologists  
physical status classification 
Clinical complete response 
Complete mesocolic excision 
Colorectal cancer 
Circumferential resection margin 
Chemoradiotherapy 
Computed tomography 
Endoscopic mucosal resection 
Endoscopic submucosal dissection 
Endoluminal ultrasonography 
Faecal immunochemical test 
Guaiac-based faecal occult blood test 
Gray 
Hazard ratio 
International Classification of Dieseases 
Inpatient registry 
Local excision 
Multidisciplinary team conference 
Magnetic resonance imaging 
Odds ratio 
Pathological complete response 
Swedish Colorectal Cancer Registery 
Transanal 
Transanal endoscopic microsurgery 
Total mesorectal excsion 
Tumour Node Metastasis staging system 
Union for International Cancer Control 
 
 
 
 
 
13 
 
Deborah Saraste 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
  
  
  
 
 
 
14 
     
BACKGROUND
 
  
Colorectal cancer 
Epidemiology 
Of estimated 3.5 million new cases of cancer in Europe every year, colorectal cancer (CRC) is 
the second most common form of cancer with 447.000 new cases, and the second most common 
cause of death from cancer with 215.000 deaths per year 1. In Sweden, the incidence is 6000 
cases per year, of which 2/3 are originating from the colon, and 1/3 from the rectum. The num-
ber of cases has increased with 70 % over the past 40 years. This is mainly due to the succes-
sively aging population, since the increase in age standardized incidence is not as pronounced. 
Overall mortality is slightly decreasing. The overall 5-year survival in CRC is around 50 %, but 
survival is clearly stage dependent. Swedish national population based data on 5-year relative 
survival is shown below 2,3.  
Table 1. Relative survival in CRC, Sweden 2007-2013.  
Relative survival,  
2007-2013 
Rectal cancer Colon cancer 
(elective sur-
gery) 
Stage I 93 % 98 % 
Stage II 82 % 93 % 
Stage III 68 % 74 % 
Stage IV 12 % 26 % 
 
Staging 
Staging of CRC is made according to the TNM staging system which classifies colorectal can-
cer according to the growth of the primary tumour (T), the regional lymph-node status (N) and 
distant metastases (M). Staging is made through physical examination, rectoscopy/endoscopy, 
imaging, surgical exploration and histopathological examination. The Union for International 
Cancer Control (UICC) and the American Joint Committee for Cancer (AJCC) collaborates in 
maintenance and revision of the system. Since Jan 1, 2010 the 7th edition of the TNM staging 
system is at use in Sweden. 
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Table 2. Tumour staging according to the TNM Classification of Malignant tumours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from TNM Classification of Malignant tumours, 7th Edition 
 
Preoperative clinical staging (cTNM) 
Colon  
Complete endoscopic examination of the colon and rectum is advised including biopsies of any 
lesions requiring surgical treatment. Chest and abdominal computed tomography (CT) is used 
for staging of the primary tumour, the lymph node status and the distant metastases. For liver 
lesions in which CT is inconclusive, further investigations with contrast enhanced ultrasound or 
MRI can be added. 
Rectum 
Digital examination followed by a rigid rectoscopy with biopsies for histopathological diagnosis 
and assessment of the distance of the tumour to the anal verge and a colonoscopy for complete 
examination of the colon are included in the primary investigation. Chest and abdominal com-
puted tomography is used for staging of distant metastases. Pelvic magnetic resonance imaging 
(MRI) is conducted in order to obtain information on the stage of the primary tumour, involve-
ment of the mesorectal fascia, extramural vascular invasion, and staging of mesorectal and pel-
vic sidewall lymph nodes, thus identifying which patients will benefit from neoadjuvant treat-
ment, and which should proceed to abdominal surgery or local excision without previous onco-
logical treatment. Endoluminal ultrasonography (EUS) can be used in early rectal cancer in ad-
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: intraepithelial or invasion of lamina propria 
T1 Invasion of submucosa 
T2 Invasion of muscularis propria 
T3 Invasion through muscularis propria into subserosa or non-peritonealised pericolic or 
perirectal tissue 
T3a Tumour extends <1 mm beyond muscularis propria 
T3b Tumour extends 1-5 mm beyond muscularis propria 
T3c Tumour extends 5-15 mm beyond muscularis propria 
T3d Tumour extends ˃15 mm beyond muscularis propria 
T4a Invasion through visceral peritoneum 
T4b Direct invasion of other organs or structures 
NX Regioinal lymph nodes cannot be assessed 
N0 No regional lymph node metastases 
N1 Metastases in 1-3 regional lymph nodes 
N1a Metastases in one regional lymph node 
N1b Metastases in 2-3 regional lymph nodes 
N1c Tumour deposits in subserosa or non-peritonealised pericolic or perirectal tissues 
without regional lymph node metastases 
N2 Metastases in 4 or more regional lymph nodes 
N2a Metastases in 4-6 regional lymph nodes 
N2b Metastases in 7 or more regional lymph nodes 
MX Distant metastases cannot be assessed 
M0 No distant metastases 
M1 Distant metastases 
M1a Metastases confined to one organ/site (including non-regional lymph nodes 
M1b Metastases in more than one organ/site or peritoneum 
16 
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dition to MRI for assessment of T-stage. The extent of locally advanced CRC or/and metastatic 
disease can be determined by positron emission tomography/computed tomography (PET/CT) 
with 18F-FDG (2-deoxy-2-[fluorine-18]fluoro-D-glucose). 
Preoperative staging is essential for the planning of further surgical and oncological treatment 
and the decision on whether curative or palliative intent is the aim of the treatment. 
 
 
 Table 3. Correlation between anatomical staging and prognostic groups 
 
 
 
 
 
 
 
 
Adapted from the American Joint Committee on Cancer Staging Manual, 7th Edition 
 
Accuracy of preoperative imaging 
Results from the MERCURY-study shows that high-resolution MRI in preoperative staging of 
rectal cancer has a high specificity for predicting the depth of tumour invasion outside the mus-
cularis propria (92.5 %) and a high specificity for negative mesorectal fascia involvement  
(92 %) when compared to histopathological assessment of the resected specimen as a reference 
standard 4,5. However, meta-analyses have demonstrated  the specificity on MRI regarding 
lymph nodes assessment is poor (71%) 6. EUS, CT and MRI in rectal cancer displays equally 
poor results regarding the specificity (78 %, 74 % and 76 % for EUS, CT and MRI respectively) 
for correct staging of lymph node involvement in rectal cancer. Regarding invasion of the mus-
cularis propria, EUS and MRI have a similar sensitivity (94 %), but EUS has a higher specifici-
ty (86 %) compared to MRI (69 %) 7. In staging of colon cancer pooled data from meta-
analyses have demonstrated a sensitivity and specificity for detection of tumour invasion  
(T-stage) to 86 % and 78 % respectively, with corresponding values for identification lymph 
node status of 70 % and 78 % respectively 8. Hence the preoperative assessment of lymph node 
metastases remains a challenge, which also has impact on the decision making and oncological 
outcome in case of local excision surgery. 
Histopathological staging (pTNM) 
The histopathology report is based on the TNM staging system and the WHO Classification of 
Tumours of the Digestive System 9. Since 2010 the 7th edition of TNM system is uniformly 
Stage T N M 
0 Tis N0 M0 
I T1-T2 N0 M0 
IIA T3 N0 M0 
IIB T4a N0 M0 
IIC T4b N0 M0 
IIIA T1-T2 N1/N1c M0 
 T1 N2a M0 
IIIB T3-T4a N1/N1c M0 
 T2-T3 N2a M0 
 T1-T2 N2b M0 
IIIC T4a N2a M0 
 T3-T4a N2b M0 
 T4b N1-N2 M0 
IVA Any T Any N M1a 
IVB Any T Any N M1b 
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used for histopathology reporting in Sweden. More than ˃ 90 % of CRC are adenocarcinomas 
originating from epithelial cells of the colorectal mucosa (other colorectal cancer types are neu-
roendocrine, squamous cell, adenosquamous, spindle cell and undifferentiated carcinomas). 
Only adenomcarcinomas are reported to the Swedish Colorectal Cancer Registry. The criterion 
of carcinoma is infiltration of the tumour through the muscularis mucosae. Previously the ter-
minology of poorly, moderately and highly differentiated cancer has been used. However, ac-
cording to the WHO 2010 classification, the use of the terms high and low grade cancer is ad-
vocated. Grading of the cancer into low grade and high grade cancer is based on the glandular 
formation, were ≥ 50 % equals low grade cancer and < 50 % equals high grade cancer. A low 
grade cancer thus corresponds to a highly differentiated cancer. The presence of a mucinous 
cancer is noted, defined as ≥ 50 % of the tumour volume being composed of extracellular mu-
cin. In addition to the TNM system, the pathology report will include information on the sub-
classification of T1 tumours according to the Kudo classification (later modified by Kikuchi), 
which divides the submucosa into thirds, sm1, sm2 and sm310,11. However, this sub-
classification cannot be accomplished if the muscularis propria is not represented in the speci-
men. 
Figure 1. Submucosal tumour invasion, sm1-3 
 
Mucosa    
Mucularis mucosa    
Submucosa  1/3    
                       2/3    
                       3/3    
Muscularis propria    
 sm1 sm2 sm3 
 
Adapted from Kudo et al., Endoscopy 1993;25:455-61 
 
Cancer growth in pedunculated polyps are classified according to the Haggitt-classification  
I-IV12. Haggitt level I-III corresponds to T1sm1 in the Kikuchi classification, whereas Haggitt 
level IV corresponds to the submucosal invasion of T1sm1-3.  
Table 4. Haggitt classification of T1 cancer in pedunculated polyps 
 Haggitt-classification Invasion to 
1 Head of polyp 
2 Neck of polyp 
3 Stalk of polyp 
4 Submucosa of underlying colonic wall 
 
   Adapated from Haggitt et al., Gastroenterology 1985;89:328-36 
The number of examined and positive lymph nodes and the presence of perineural growth, 
small-vessel lympho-vascular growth or extramural venous invasion are noted in the histo-
pathology report, as are the minimum circumferential and longitudinal resection margins and if 
these are microscopically free of tumour. In case of neo-adjuvant therapy the tumour regression 
grade (0-3) is noted. 
18 
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Studies have demonstrated that an increasing number of examined lymph nodes after resection 
surgery in colon cancer is associated with increased survival in stage II and III cancer 13. The 
reasons for this are partly that a larger number of examined nodes decreases the risk of under-
staging, but also that increased focus on and awareness of the importance of histopathology in 
the treatment of colorectal cancer has improved the quality of the histopathological               
assessment 14. Detection and examination of at least 12 lymph nodes is considered a quality 
indicator of both the surgical resection and the histopathological examination 15. 
The issue of tumour deposits needs some extra attention. In previous versions of the TNM man-
ual, tumour deposits were classified as either as discontinuous extension (T3) or as positive 
nodes depending on size and shape. To avoid misclassification of the N-stage, consequently 
affecting adjuvant treatment and survival, tumour deposits are now classified as N1c in absence 
of other positive nodes. According to TNM 7 tumour deposits “represent discontinuous spread, 
venous invasion with extravascular spread (V1/2) or a totally replaced lymph node (N1/2). If 
such deposits are observed with lesions that would otherwise be classified as T1 or T2, then the 
T classification is not changed, but the nodule(s) is recorded as N1c. If a nodule is considered 
by the pathologist to be a totally replaced lymph node…it should be recorded as a positive 
lymph node”.  
 
Multidisciplinary team conferences (MDT) 
In multimodal contemporary treatment of patients with colorectal cancer, the involvement and 
special competences of different specialities are necessary. Not only staging and planning of 
surgery, but also timing, sequencing and strategy concerning neo-adjuvant and adjuvant treat-
ment in relation to surgery is needed to optimise treatment for the individual patient. The physi-
cal and mental status and wishes of the individual patient are taken into account in addition to 
the characteristics of the tumour. 
Colorectal surgeons, radiologists, pathologists, oncologists and specialised nurses participate in 
the team, and when needed, liver surgeons attend. Every individual patient is discussed pre- and 
postoperatively, and sometimes multiple assessments are necessary, depending on the com-
plexity of the multimodal treatment.  
In a systematic review Wright et al. concluded that MDT conferences (not only confined to 
colorectal cancer) resulted in positive patient outcomes in terms of diagnosis and/or treatment 
planning, patient survival and satisfaction, and clinician satisfaction in terms of communication 
and cooperation16. Specific studies on colorectal cancer have shown that patients with rectal 
cancer are more completely staged than patients with colon cancer, at least in stage IV          
disease 17. Fewer cases of involved circumferential resection margins (CRM+) are seen among 
patients with rectal cancer who are discussed at MDT conferences 18. 
The Swedish board of Health and Welfare states that for patients with CRC, “the healthcare 
provider should always evaluate different treatment options…in a multidisciplinary              
conference” 19. According to Swedish National quality data on patients undergoing elective 
surgery (polypectomies excluded), 83 % and 96 % of patients with colon and rectal cancer re-
spectively are assessed at a preoperative MDT-conference. 
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Surgical treatment of colorectal cancer 
Colon cancer 
The introduction of the Total mesorectal excision (TME)-technique in rectal cancer dramatical-
ly decreased local recurrence rates after surgery 20. In colon cancer surgery attempts to standard-
ize the surgical resection technique came later, with the introduction of complete mesocolic 
excision (CME) for colon cancer as proposed by Hohenberger et al. in Erlangen. In analogy 
with the TME-technique in rectal cancer surgery, the CME technique is based on surgical dis-
section along embryological planes with sharp separation of the visceral and parietal tissue lay-
er. Central ligation of supplying arteries relevant for the tumour affected segment is advocated 
and lymph node yield is thus maximized along with an intact embryological envelope around 
the specimen 21. In the Erlangen-material, the 5-year cancer-specific survival rate was 89 % in 
patients undergoing curative resections in stage I-III tumours. The local recurrence rate by the 
end of the study period (1978-2002) was 3.6 %. However, the optimal extent of the mesocolic 
resection and central vascular ligation and how this affects long term oncological results outside 
a single centre is not clear. Meta-analyses of CME surgery demonstrates that CME surgery re-
moves more tissue around the tumour and harvests more lymph nodes, but data are sparse re-
garding the long term survival benefit compared to traditional radical resection of the colon 22. 
However, a recent study by Bertelsen et al. comparing CME to conventional colon cancer sur-
gery, concluded that disease-free survival was higher after CME, in all included stages (I-III) 
with a 4-year survival of 86 % compared to 73 % (p = 0.0014) after CME and non-CME sur-
gery respectively 23. 
Laparoscopic resections in colon cancer  
Large randomized multi-institutional trials have shown that long-term oncologic results in terms 
of disease-free and overall 5-year survival, and overall recurrence rates are similar comparing 
laparoscopic and open resections for colon cancer 24. Short term oncologic results such as posi-
tive resection margins, number of lymph nodes removed and morbidity and mortality are also 
comparable 25. 
Rectal cancer 
Total mesorectal excision (TME) 
The modern era of rectal cancer surgery began with the introduction of the Total mesorectal 
excision (TME)-concept as proposed by Bill Heald in 1982 20. Opposite to the blunt resection 
technique previously used, the surgical dissection introduced by Bill Heald is sharp and under 
direct vision, and includes a complete excision of the mesorectum along the embryological 
avascular planes between the mesorectum and the autonomic nerve plexae and pelvic fascia. 
The inferior mesenteric artery is ligated in proximity to the aorta to ensure resection of lymph 
nodes relevant for drainage of the tumour. With this approach 5–year local recurrence rates of 
3.7 % and 5-year survival of 87 % in patients with Dukes stage A-C were reached after surgery 
without neoadjuvant or adjuvant treatment, which at the time was astonishing results compared 
to previous recurrence rates of 40 % 26. Corresponding survival and local recurrence rates in 
national Swedish population based data shows a 3-year relative survival of 90 % in patients 
20 
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with stage I-III disease (equals Dukes stage A-C) after resection surgery (2007-2013) and cu-
mulative 5-year local recurrence rates of 7 % (1995-2008) in patients with stage I-IV disease, 
including patients with and without neoadjuvant radiotherapy 3. 
Anterior resection (AR) 
The dissection is performed according to the principles of TME-surgery. A distal resection 
margin of 1 cm is generally accepted in low-lying tumours to promote sphincter-preserving 
surgery instead of abdominoperineal excision, and in patients receiving pre- or postoperative 
radiotherapy a margin even less than 1 cm is discussed 27. In more proximal tumours, the 
mesorectal excision is partial since the complete mesorectum is not excised down to the pelvic 
floor, and a resection margin of 4-5 cm is advocated to include sufficient mesorectal tissue in 
the specimen. Short term morbidity and long term oncological results are comparable in TME 
and partial mesorectal excision (PME) 28. 
The anastomosis can in high tumours or in cases of a colo-anal anastomosis be hand sewn, but 
is otherwise created with a circular stapling device. A side-to-end anastomosis or J-pouch is 
advocated in low lying tumours, in order to improve functional results 29,30. 
Abdominoperineal excision (APE) 
To ensure an adequate distal resection margin in low lying tumours, or in case a poor functional 
outcome is expected with an anastomosis, or if numerous risk factors for anastomotic leakage 
are present, APE is performed. 
While oncological results improved in AR after the introduction of the TME-technique, no such 
effect was observed in APE. In the classical APE the dissection follows the levator muscles to 
the sphincter complex, hereby creating a “waist” of the specimen. The proximity to the sphinc-
ter complex in the “waist”  increases the risk of CRM involvement and tumour perforation and 
thus increases the risk of local recurrence and impaired survival in patients operated with APE 
compared to AR 31. In order to improve these results the Extralevator APE (ELAPE) was intro-
duced. The procedure allows mobilization of the mesorectum, only until the proximal origin of 
the levator muscle, after which a stoma is formed and the abdomen is closed. The perineal 
phase of the operation is performed with the patient in preferably prone position to improve 
visualisation. The sphincter complex and the levator muscles are included in the resection. To 
further improve visualization the coccyx can be removed. This technique eliminates the “waist” 
of the specimen, and results in a cylindrical specimen, thereby reducing resection margin in-
volvement from 41 % to 15 % and intraoperative perforations from 23 % to 4 % compared to 
the conventional APE, as demonstrated by surgeons in Stockholm and Leeds after the introduc-
tion of  ELAPE 32.  A meta-analysis from 2014 comparing ELAPE to conventional APE con-
firmed these results demonstrating a significant reduction in the rate of involved resection mar-
gins, intraoperative perforations and local recurrence rates in favour of ELAPE 33. 
Further modification of this concept into intersphincteric APE, ELAPE and ischioanal APE has 
been proposed to meet the different indications for APE 34.  
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Hartmann’s procedure 
In patients with high comorbidity or with a poor sphincter function Hartmann’s procedure could 
be considered as an alternative to AR or instersphincteric resection. The dissection follows the 
same principles as for AR, but instead of an anastomosis, a sigmoidostomy is created, and the 
rectal stump is closed. 
Laparoscopic and robotic surgery 
Laparoscopic and robotic surgery for rectal cancer is increasingly gaining ground as an alterna-
tive to open surgery. A Cochrane report was undertaken 2014 to evaluate differences in short- 
and long-term outcomes, comparing laparoscopic versus open total mesorectal excision for rec-
tal cancer. Results regarding five-year disease-free survival, local recurrence rates and overall 
survival were similar between the laparoscopic and open TME groups, as were the number of 
resected lymph nodes and the surgical resection margins. No difference was seen between the 
groups regarding 30-day morbidity. Similar anastomotic leakage rates were demonstrated  
(7.7 % vs. 6.3 %; laparoscopic vs. open), however fewer wound infections and less postopera-
tive bleeding was seen in the laparoscopic group. No differences were demonstrated in quality 
of life regarding functional recovery, bladder and sexual function. In the laparoscopic group 
length of stay was reduced by two days and time to first defecation was shorter, but costs were 
higher for laparoscopicsurgery 35. 
With robotic surgery in rectal cancer, similar long term oncological results in terms of 5-year 
overall survival, disease free survival and local recurrence rates have been demonstrated com-
pared to laparoscopic surgery. No benefits have been observed compared to laparoscopic sur-
gery but the cost is increased 36. Previous studies of short term outcome have displayed a longer 
operation time in the robotic group, but otherwise similar results regarding overall major com-
plications and quality of the resected specimen in terms of distal and circumferential resection 
margins and harvested lymph nodes 37. 
 
Complications, morbidity and mortality after colorectal cancer  
surgery 
Total complication rates of up to 50 % have been reported after rectal cancer surgery 38. 
A recent meta-analysis including all prospective studies on surgery with AR and APE for rectal 
cancer, 1990-2008, demonstrated an anastomotic leakage rate of 11 % and a pelvic sepsis  
(defined as either anastomotic leak or pelvic abscess) rate of 12 %. Postoperative mortality was  
2 % 39. After APE, perineal wound complications are a common problem. A multicenter study 
by West et al., 2010, reported an overall wound complication rate of 38 % and 20 % after extra-
levator- and standard APE respectively 40. 
Complication rates after surgery for colon cancer are generally lower compared to rectal cancer 
surgery, but total complication rates of 20-33 % and anastomotic leakage rates of 3 % after open 
surgery for colon cancer are reported 41,42. Anastomotic leakage is a serious complication with 
an in-hospital mortality of 19 % compared to 3 % in patients without leakage after colon cancer 
surgery, and a decreased 5-year over-all and disease free survival 43.  
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Functional aspects 
Sexual, urinary- and bowel function are all affected by rectal cancer surgery and the pelvic dis-
section itself, and can be further impaired by preoperative (chemo) radiotherapy. 
Low anterior resection syndrome (LARS) 
 LARS is a condition characterised by incontinence, urgency, fragmented stool and frequent 
bowel movements after anterior resection surgery. With a validated scoring system for evalua-
tion of the presence and severity of LARS, a Danish study included all patients who underwent 
curative resection for rectal cancer in Denmark 2001-2007. Major symptoms of LARS were 
observed in 41 % of the patients. Risk factors associated with major LARS were neoadjuvant 
therapy (short- or long-course radiotherapy or chemoradiotherapy), anastomotic leakage, age  
≤ 64 years at surgery, and female gender. The odds of LARS were higher for long-course 
chemo-radiotherapy vs. short-course radiotherapy and for TME vs. PME 44.  
Sexual and urinary dysfunction 
Sexual dysfunction after rectal cancer surgery is common both in women and men, affecting 
their quality of life. A questionnaire-based study on 81 women and 99 men who had undergone 
APE, AR or transanal excision reported that 32 % of women and 50 % of men were sexually 
active after surgery, compared to 61 % and 91 % respectively before surgery (p< 0.04). Both 
genders reported a negative body image. Twenty-nine percent of the women, and 45 % of the 
men reported that surgery hade made their sexual lives worse. More than 80 % of the patients 
reported that their ostomy caused a negative change in their sexual life 45.  
Urinary dysfunction is a common problem after rectal cancer surgery. Comparing the outcome 
after ELAPE and APE, 46 % of patients experienced erectile dysfunction and 46 % urinary dys-
function after ELAPE. The corresponding rates after APE were 33 % and 17 % respectively 46 .  
Stoma 
Ostomies are associated with a number of possible complications such as prolapse, retraction, 
stenosis, parastomal hernias and problems for the patient to handle the stoma in practical and 
psychological terms. Wound infections after creation of diverting loop ileostomies and loop-
colostomies are reported in 3 % and 5-20 % respectively and dehydration is a common cause of 
postoperative morbidity in patients with loop-ileostomies, affecting up to 30 % of the  
patients 47,48. Furthermore loop-ileostomy closure is associated with a morbidity and mortality  
of 17 % and 0.4 % respectively 47. Nevertheless, to reduce the sequel of an anastomotic leakage, 
a defunctioning stoma after anterior resection of low rectal cancers is advocated. A multicentre 
randomized trial comparing patients undergoing low anterior resection for rectal cancer with or 
without a defunctioning stoma showed  a difference in symptomatic leakage rates of 10 % vs. 
28 % in the stoma and non-stoma groups respectively49.  However, the same study showed that 
after a median follow up of 42 months, 14 % of those with a temporarily intended defunctioning 
stoma never had it reversed. Regarding quality of life in patients with a permanent colostomy 
after resection of a rectal cancer with APE or Hartmann’s procedure, compared to patients un-
dergoing anterior resection with no stoma, a recent Cochrane review could not draw any firm 
conclusions in favour of either group 50. 
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Local excision (LE) techniques in early rectal cancer 
Transanal surgery 
The possibility of transanal resection is restricted to tumours in the lower part of rectum. When 
used for resection of malignant lesions, studies have showed high local and overall recurrence 
rates , and impaired survival in T2 tumours compared to TME surgery 51,52. One of the explana-
tions for this is the problem of positive resection margins. However, since the introduction of 
transanal endoscopic microsurgery, and the evolution of endoscopic resection techniques, the 
use of transanal resection has decreased. 
 
Transanal endoscopic microsurgery (TEMS) 
Technique  
In the beginning of 1980s the TEMS instrument and technique was developed by Gerhard 
Buess 53. TEMS is a minimally invasive technique for local excision of rectal neoplasms. The 
instrument consists of a rigid rectoscope, 4 cm in diameter, through which carbon dioxide is 
insufflated, and instruments are inserted. Pneumorectum is established and the operating field is 
visualized with magnification, either thorough a stereoscope or via connection to a laparoscopic 
video stack. Different single port access systems have been introduced successively over the 
years, e.g. Trans Anal Minimally Invasive Surgery (TAMIS), in which the basic concept of es-
tablishing transanal access to the rectum and creating a pneumorectum is the same as in TEMS, 
but where the devices and their limitations differ. However, TEMS is so far the more estab-
lished technique. 
An important limitation of TEMS and all other local excision techniques is the inability to ex-
cise the lymph nodes of the mesorectum. Possible lymph node metastases will therefore not be 
removed nor diagnosed, and hence there is a risk of recurrence and/or under-staging, which is 
one contributing cause of the questioned oncological safety. 
Morbidity and mortality 
After the TEMS procedure postoperative transient urinary retention has been reported 54. No 
long term effects on urgency or continence or quality of life have been observed 55. Multicenter 
data have shown an overall complication rate of 15 % and a mortality of 1 % 56 . The rate of 
intraoperative peritoneal perforations is 5.8 %, which in 11 % of cases necessitated conversion 
to laparoscopic or abdominal resection surgery in a series of patients undergoing of TEMS re-
sections of benign and malignant lesions 57. The hospital stay and operation time is shorter and 
the risk of postoperative complications is smaller (p < 0.0001) in TEMS compared to abdominal 
resection surgery for patients with T1 and T2 cancers 58. 
As opposed to APE all local excision techniques enables the resection of early distal rectal can-
cers without the need of a permanent stoma. 
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Endoscopic resections 
The technical development and performer skills in the area of endoscopic resection are under 
rapid progress. Until recently endoscopic mucosal resection (EMR) was the option for endo-
scopic removal of, predominantly, benign lesions. A limitation of this technique is the inability 
to resect lesions > 20 mm en-bloc, leading to a high rate of local recurrence. With the introduc-
tion endoscopic submucosal dissection (ESD) meta-analyses have demonstrated a higher radical 
resection rates (88 %) with acceptable complication rates (1 % of the complications necessitated 
surgical intervention), making ESD evolve as a possible option for local resection of CRC in 
addition to benign lesions 59. ESD was originally developed for early gastric cancer and the ap-
plication on colorectal lesions has been more technically demanding with a higher risk of perfo-
ration. The ESD technique uses several different knifes as cutting devices and removes a lesion 
in three steps: 1) injection of fluid into the submucosa to elevate the lesion from the muscular 
layer, 2) pre-cut of the surrounding mucosa, 3) dissection of submucosal connective tissue be-
neath the lesion. Small studies have compared ESD to TEMS for resection of early rectal cancer 
regarding en-bloc and R0 resection rates and local recurrence rates. After follow-up until 3 
years, no significant difference between the two methods was seen 60,61. However, the number 
of lesions extending into the submucosa, i.e. true colorectal cancers, was small, and a large pro-
portion of these required additional surgery, making the issue of local recurrence in case of can-
cer difficult to assess. 
Resection with ESD is possible in both colon and rectum, but the risk of perforation increases in 
the proximal colon and therefore the primary interest has been lesions in the rectum, where ESD 
could evolve to an alternative or complement to TEMS in benign, and possibly in malignant 
lesions. The location of the rectum, surrounded by perirectal fat and in part distal to the perito-
neal reflection, enables full thickness resections of lesions in the rectal wall by local excision 
techniques. This is not convenient in the colon, where a full thickness resection would create a 
perforation into the peritoneal cavity. However, studies on porcine models indicate that endo-
scopic full thickness resections with or without laparoscopic assistance could evolve as an op-
tion in the future 62. 
 
Oncological results after local excision 
The literature on oncologic outcome after TEMS is divergent, as are the opinions on the onco-
logical safety of TEMS and local excision techniques in general, and to which extent TEMS 
should be used in CRC-surgery with curative intent. Some obscurity also exists in the literature 
regarding the concept of local excision, which can include both transanal excisions and TEMS 
as well as endoscopic resections. This makes it, in some studies, difficult to separate the results 
of each technique. 
In a meta-analysis from 2011 comparing TEMS to abdominal resection surgery for T1 and T2 
rectal cancer a higher overall all and  local recurrence rate after TEMS compared to abdominal 
resection surgery was observed, partly due to positive resection margins, but no difference in  
5-year survival was observed 63. Local recurrence rates are the very central problem regarding 
the oncologic safety of TEMS and local excision in general, due to the fact that possible meta-
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static nodes cannot be resected along with the surgical specimen. Another problem, especially 
regarding transanal excision, has been the high rates of positive resection margins. However, 
compared to transanal excision TEMS has a lower rate of positive resection margins and a long-
er disease-free survival 63 .Two large studies with data from the American National Cancer Da-
tabase have looked at trends of LE over time in comparison to abdominal resection surgery in 
stage I rectal cancer. You et al. looked at patients diagnosed with rectal cancer 1989-2003, 
comparing local excision to “standard resection”, however not specifying local excision as 
TEMS or TA. The results showed a local recurrence rate of 12.5 % vs. 6.9 % in T1-tumours and 
22.1 % vs. 15.1 % in T2 tumours after LE and standard resection respectively. No difference in 
overall survival with regards to type of surgery was seen. By the end of the study, in 2003, 44 % 
of the T1-tumours were resected with LE. In a later study, also from the American National 
Cancer database, with data on patients with stage I rectal cancer, by 2010, 55 % of patients with 
T1-T2 tumours were treated with LE 64. 
For comparison to the study by You et al., data on Swedish patients with stage I, i.e. both T1 
and T2, rectal cancers, diagnosed 1995-2001, resected with local excision (including transanal 
resection, TEMS and polypectomies) demonstrated 5- year local recurrence rates of 7 % and a 
5-year survival of 95 %.  In this material 12 % of all patients with stage I disease underwent 
local excision (including TEM, transanal excision and endoscopic resection) 65. Compared to 
the American material, the Swedish data displays low local recurrence rates, since stage I in-
cludes both T1 and T2 tumours, but still a very restrictive use of local excision as a treatment 
strategy for rectal cancer. 
 
The risk of lymph node metastases 
The central problem of oncological safety after local excision in (colo)rectal cancer revolves 
around the inability of present imaging techniques to correctly predict lymph node metastases 
and the inability of the any local excision technique to resect these lymph nodes en bloc with 
the tumour. Because of this, many have tried to assess the risk of lymph node metastases in or-
der to conclude which patients could safely be offered a local excision procedure instead of an 
abdominal resection. 
Since long the extent of tumour invasion into the bowel wall is considered a risk factor for 
lymph node metastases.  The risk is 3-4, 8-11, 23-24 % in sm1, sm2 and sm3 tumours respec-
tively 66,67. The risk in T2 tumours is 26 % 68. In addition to tumour stage, a large number of risk 
factors have been analysed in different studies. Female gender, lymphatic invasion, venous in-
vasion, high grade cancer, increasing tumour diameter and tumour in the lower third of the rec-
tum are some of the risk factors which have been addressed and noted as risk factors in different 
studies 67,69,70. Two recent meta-analyses by Bosch et al. and Glasgow et al. have assessed fac-
tors predicting lymph node metastases in T1 and T1-T2 CRCs respectively 71,72. In both studies, 
lymphatic invasion was the strongest predictor of lymph node metastases (expressed as an OR 
8.6 and RR 5.2 respectively). In addition to lymphatic invasion, tumour depth (T2 vs. T1, OR 
2.6) and poor differentiation (OR 2.4) was reported as the other two strongest predictors in the 
study by Glasgow et al., who also looked at a rectal cancer subset, where poor differentiation at 
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the invasive front (OR 6.1) and tumour budding (OR 5.8) were most predictive of lymph node 
metastases. There was an evident heterogeneity among the studies included in the meta-
analysis, reflected by the fact that 42 histopathological features were analysed, but only 41 % of 
these were reported in  > 2 studies. In the study by Bosch et al., submucosal invasion > 1mm 
(RR 5.2), budding (RR 5.1) and poor histological differentiation (RR 4.8) were the strongest 
predictors of lymph node metastases, in addition to lymphatic invasion. 
To make clinical use of this information some authors have tried to make a decision tool of their 
findings calculating the additive effect of multiple risk factors. One example is a study by Ko-
bayashi et al., where risk factors for lymph node metastases in patients with lower rectal cancer 
were assessed. The risk ranged from 1 % in male patients with well differentiated T1-tumours, 
to 37 % in female patients with non-well differentiated T2-tumors 68. The above mentioned me-
ta-analyses and example highlights that stage per se is not the strongest determinant of lymph 
node metastases. A low risk T2 cancer can have a lower risk of lymph node metastases than a 
high risk T1 cancer. Many of the studies evaluating the risk of lymph node metastases selected a 
limited number of potential risk factors for analysis, and to get an overall view, in which these 
theoretical calculations can be translated into practical advice and guidelines on which patients 
who, with preserved oncological safety, can be recommended a local excision procedure, re-
mains a challenge. 
 
Oncological treatment of non-metastatic CRC 
Neoadjuvant radiotherapy (RT) 
In patients with rectal cancer preoperative short-course radiotherapy (RT) 5x5 Gray (Gy) have 
in randomised trials demonstrated reduced local recurrence rates with > 50% compared to sur-
gery alone, whereas effects on survival benefits are more uncertain 73-75. The timing of surgery 
in relation to the radiotherapy and the question on whether short- (5 Gy x 5 days) or long-course 
(1.8-2.0 Gy x 25-28 days) radiotherapy is more favourable is still under debate. Results from the 
Stockholm III- trial exploring this matter will soon be available. This 3-armed randomised trial 
is comparing 5 Gy x 5 with immediate surgery, 5 Gy x 5 or 2 Gy x 25 with delayed (4-8 weeks) 
surgery, with local recurrence as the primary outcome 76.  
 
Neoadjuvant chemoradiotherapy (CRT) 
In locally advanced rectal cancer, preoperative CRT is advocated. Compared to RT, CRT im-
proves local control, time to treatment failure and cancer specific survival 77.  The standard CRT 
regimen consists of long course radiotherapy with concomitant 5-fluorouracil (5-FU) given ei-
ther as bolus with leucovorin (FLv), as a prolonged infusion or as oral capecitabine.  
Based on the risk of local recurrence, different algorithms for neoadjuvant treatment of rectal 
cancer without distant metastases have been proposed. The current European Society for Medi-
cal oncology (ESMO) Guidelines for rectal cancer proposes a categorisation into four risk 
groups; Very early, Early (Good), Intermediate (Bad), Advanced (Ugly)78.  
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   Table 5. Treatment algorithm based on the risk of local recurrence in non-metastatic rectal cancer 
 
 
 
 
 
 
 
 
 
 
MRF (meso rectal fascia), EMVI (extra mural vascular invasion), RT (radiotherapy), CRT (chemoradiotherapy). 
Risk Group (cTNM) Therapeutic options 
Very Early: 
T1sm1N0, possibly sm2 
 
Local excision (TEM). In case of poor prognostic signs; sm-stage ≥2/ 
poor differentiation/vascular invasion, immediate abdominal TME 
surgery is recommended 
Early (Good): 
T1-T2, T3a(b)N0 (middle/high tumour), N1 
(high tumour) 
MRF-, EMVI- 
Direct TME. In case of poor prognostic signs; crm+/N2 postoperative 
CRT or CT is recommended. 
Intermediate (Bad): 
very low T2, T3 (not T3a (b) in middle/high 
rectum), limited T4aN0 
N+, EMVI+, MRF- 
 
Preoperative short course RT (5x5 Gy) or CRT followed by TME within 
10 days 
Locally advanced (Ugly): 
T3-T4b, MRF+, lateral node+ 
Preoperative CRT followed by surgery within 6-8 weeks. 
Optional in patients unfit for CRT is RT (5x5 Gy) followed by surgery 
after 8 weeks. 
 
     Adapted from Glimelius et al., Ann Oncol 2013;24 Suppl 6:vi81-8 
According to this algorithm a very low proportion of the “Very early” and “Early” group of 
patients with rectal cancer would be subject to neo-adjuvant treatment. However, national Swe-
dish data 2007-2010 shows that in the group of patients undergoing abdominal resection surgery 
for very early and early tumours, 54 % receive preoperative RT and 2 % CRT 79. Thus it seems 
that our aim of reducing local recurrence rates is resulting in a possible overtreatment with 
(C)RT. 
 
Adverse effects after neoadjuvant RT and CRT 
Preoperative (C)RT has both short- and long-term side effects. Immediate toxicity and side ef-
fects include fatigue, nausea, diarrhoea, erythema and acute lumbosacral plexopathy. 
In the Dutch TME study comparing 5 Gy x 5 and surgery vs. surgery alone for rectal cancer, 
toxicity effects were negligible and no difference in morbidity was seen. Overall postoperative 
complication rates was higher in the RT+ group ( 48 % vs. 41 %), mainly due to more perineal 
wound complications 80.  Sexual functioning was impaired in both males and females in the 
RT+ group, with significantly decreased ejaculation and erection function among men receiving 
RT 81. Effects on Leydig cell function have been reported in other studies, increasing the risk of 
testosterone deficiency in males following RT 82. Questionnaire-results after The Swedish Rec-
tal cancer trial showed that incontinence for loose stools, urgency and emptying difficulties 
were all more common after RT and 30 % of the patients in the RT group experienced an im-
pairment of their social lives due to bowel dysfunction compared to 10 % in the surgery only 
group 83. Symptoms of LARS are impaired by short- and long course radiotherapy or chemora-
diotherapy compared to surgery only 44. The is also an increased risk of gastrointestinal disor-
ders, neurological problems, pelvic hip fractures and secondary malignancies after radiotherapy 
84. 
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Adjuvant chemotherapy 
Colon cancer 
Adjuvant chemotherapy with 5-FU and oxaliplatin after resection surgery of the primary tumour 
reduces the risk of death with 3-5 % in stage II and 15-20 % in stage III disease 85. European 
guidelines state that, following surgery in stage III colon cancer, six months of combination 
therapy of oxaliplatin and 5 FU+ leucovorin or oxaliplatin and capecitabine is recommended 85. 
In stage II, adjuvant therapy is not routinely used. However, a division of stage II into high and 
low risk groups according to tumour – related risk factors should guide the decision of giving 
adjuvant chemotherapy, at least with 5-FU, to high-risk stage II patients, with at least one of the 
following risk factors: lymph node sampling < 12, poorly differentiated tumour, vascular or 
perineural invasion, pT4 stage, clinical presentation with occlusion or perforation 85. 
Rectal cancer  
Randomised trials exploring the effect of adjuvant chemotherapy in rectal cancer after preopera-
tive CRT and surgery have demonstrated conflicting results regarding the benefit of overall sur-
vival and recurrence, and a meta-analysis by Bujko et al. concluded that there was no evidence 
to recommend adjuvant chemotherapy  in patients who had already received neoadjuvant  
CRT 86. However in patients who have not received neoadjuvant treatment, postoperative CRT  
is, according European guidelines, recommended in case of a positive resection margin 
(CRM+), perforation in the tumour area or in cases of a high risk of local recurrence  
( ≥ pT3b and/or N+) 85. 
 
Complete response and organ preservation in early rectal cancer 
Much questioned when published in 2004, Habr-Gama et al. presented observations on “com-
plete response” after neoadjuvant therapy with CRT (50.4 Gy + FLv) in rectal cancer. Clinical 
complete response (cCR) is defined as the absence of any clinically detectable residual tumour 
after neoadjuvant therapy, and pathologic complete response (pCR) as the absence of viable 
tumour cells after histopathological examination of the resected specimen. In the Habr-Gama 
study clinical complete response was obtained in 27 % of the patients and examination was 
done 8 weeks after completed CRT. The 5-year overall and disease-free survival was 100 % and  
92 % respectively in the group with complete response, and 10-year overall and disease-free 
survival was 100 % and 86 % respectively 87. However, the concept of complete response and a 
subsequent “wait-and-watch” policy (omission of surgery with follow-up) is now accepted and 
has increased the interest in possible multimodal treatment strategies aiming at organ preserva-
tion in early rectal cancer. 
CRT is routinely used in advanced rectal cancer for downstaging of the tumour and mesorectal 
nodal metastases. Current ideas advocate that these effects could also be of use in early rectal 
cancer thereby reducing the rate of margin involvement and decreasing local recurrence rates 
after local excision. When combining neoadjuvant CRT and local excision, the tumour, even in 
case of complete response, could be removed, with the low morbidity and good functional re-
sults known from local excision techniques, but without the oncological drawbacks of these 
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techniques. Histopathological evaluation of the specimen would reveal both pCR and tumours 
with adverse features for which additional surgery should be considered. However, the adverse 
effect of CRT when used for early rectal cancer is an issue that needs further evaluation. 
In 2012, Lezoche et al. presented results from a small (50 patients in each arm) randomised trial 
where patients with cT2N0MO underwent long-course CRT (50.4 Gy + 5-FU) followed by ei-
ther TEMS or TME-surgery with a median follow-up of 10 years. All patients underwent R0-
resections and there was no statistically significant difference in cancer related or overall sur-
vival between the groups. Local recurrence rates were 8 % in the TEM group and 6 % in the 
TME group 88. 
A number of ongoing trials are investigating the possibilities of combining (C)RT and LE in 
early rectal cancer. The ACOSOG Z6041single arm multi-centre phase II American trial is in-
vestigating long-course CRT (50.4 Gy + Capecitabine + Oxaliplatin) + LE (either transanal 
excision or TEMS) with surgery 8 weeks after completed CRT in patients with cT2N0M0 rectal 
cancer. For the primary outcome which is 3-year disease-free survival, data are not yet availa-
ble. Secondary endpoints have been analysed showing a 44 % complete pathologic response 
rate, a high rate (99 %) of negative resection margins, but a rather high toxicity after CRT (39 % 
of patients developed grade ≥ 3 complications). The accuracy of cCR (defined as complete dis-
appearance of the tumour on proctologic examination) to predict pCR was evaluated, demon-
strating a sensitivity and specificity 85 % and 67 % respectively 89. 
In the ongoing CARTS study patients with cT1-3N0MO tumours below 10 cm from the anal 
verge are included. Neoadjuvant CRT is given as 50 Gy + Capecitabine. The study is a non-
randomised feasibility study and the primary outcome measure is the number of patients with 
complete response after CRT and TEM, performed 8-10 weeks after completion of CRT. Sec-
ondary outcomes will be local recurrence rates and quality of life 90. 
The TREC study has a little different approach. The aim of this phase II study is to determine 
the feasibility of randomising patients with early (T1-2N0M0) rectal cancer to either radical 
TME surgery or short course preoperative RT (5 Gy x 5) with TEMS after 8-10 weeks 91. 
The results of these trials will be interesting since (C)RT is added to the potentially curative 
treatment of, at least, T1 tumours with TEMS alone. The neoadjuvant treatment can add bene-
fits in terms of downstaging, less involved resection margins and decreased local recurrence 
rates. However, it will also add morbidity. If we were to adapt the new strategies of heavy pre-
operative oncological treatment for early rectal cancer it would change the way we presently 
look upon the risk-benefit ratio of neoadjuvant treatment and could increase the risk of over-
treatment in early rectal cancer. 
 
Screening for colorectal cancer 
Introduction 
Screening implies testing for a disease in apparently healthy individuals with no symptoms of 
disease. The purpose in cancer screening is to detect tumours at an early stage or even as pre-
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cancerous lesions, thereby reducing disease-specific mortality.  In CRC screening, the detection 
of both cancer and adenomas are considered important since there is a common notion that ade-
nomatous polyps are precursors of CRC, and that removal of these polyps will reduce the inci-
dence and mortality in CRC 92-94. However, potential negative side effects and risks of the 
screening procedure itself and of subsequent interventions have to be taken into account and 
have to be in balance with the benefits of screening. 
 
Evidence-based background for CRC screening 
Faecal screening tests 
Guaiac based faecal occult blood test (gFOBT) 
These tests are based on guaiac which is a tree extract that reacts with haem-part of haemoglo-
bin in faeces, but a risk of false positive results from non-human haemoglobin exists. Also 
vegetable peroxidases can interfere with the reaction. Hence, dietary restrictions omitting red 
meat, fresh fruit, vitamin C, iron preparations, ASA and NSAIDS were initially mandated, but 
are being abandoned, since their effect on the outcome is moderate while they negatively affect 
compliance. The test kit requires two samples from each of three consecutive stools. The result 
is a qualitative measurement of a methylene blue dye and there are different algorithms used in 
different screening programmes to define test positivity. The test can be rehydrated, which has 
proven to improve sensitivity, but also to decrease the positive predictive value of the test. Spec-
ificity differs in studies within a range of 90-98 % specificity for CRC and 91-99 % for adeno-
mas, while the sensitivity range is 31-64 % for CRC and 14-41 % for adenomas 95. 
In the 1990s, results from three large randomised trials in Nottingham, Funen and Minnesota 
were published, demonstrating a mortality reduction in colorectal cancer following screening 
with gFOBT. A fourth, Swedish trial was also initiated in the 1990s, however results were not 
reported until 2008. The Nottingham trial and Funen trials both compared biennial screening 
with gFOBT followed by colonoscopy when positive, to non-screening, and demonstrated a 
CRC mortality reduction in the screening group with 15 % and 18 % respectively 96,97. The 
Minnesota trial had three arms, comparing annual or biennial screening with gFOBT to a con-
trol group without screening. In the first 13-year follow-up a 33 % reduction of mortality in 
CRC was observed only in the annual screening group, compared to the controls and the bienni-
al group, in which no statistically significant reduction in mortality was seen 98.  However, after 
18 years of follow-up, a cumulative mortality reduction in CRC of  21 % could be demonstrated 
in the biennial group compared to the control arm 99. In all the trials a shift towards earlier tu-
mour stages were noted in the screening groups. The Swedish randomised trial comparing a 
gFOBT screening cohort to a non-screened population reported similar results with a 16 % re-
duction in mortality from CRC in the screening group 100. The age span of screening was heter-
ogeneous between the trials including individuals 45-74 years in the Nottingham and Funen 
trial, 50-80 years in the Minnesota trial and 60-64 years in the Swedish trial. 
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Faecal immunochemical tests (FIT) 
These kinds of tests use antibodies raised against the globin part of haemoglobin and are specif-
ic for human blood. One faecal sample is enough and the measurement is quantitative. Sensi-
tivity is determined by the selected cut-off concentration of haemoglobin. Sensitivity for CRC is  
82-92 % and for adenomas 30-34 % while specificity is 90-97 % for CRC and 91-98 % for ade-
nomas at the recommended cut-off level of 100 ng/ml 95. The compliance in FIT is higher than 
after FOBT 101. One of the reasons for this is probably that only one sample is required, com-
pared three samples in gFOBT. 
Stool DNA 
This technique investigates the presence of abnormal DNA methylation products in faeces. 
Thus, stool DNA tests have the potential to detect a neoplasm in the absence of bleeding. Meta-
analyses suggest that stool DNA markers have a higher sensitivity for detection of CRC  
(52-91 %) and adenomas compared to one-time FOBT (13-35 %) 102. However, there is no set 
standard for the number and type of markers that should be included in the test to reach the re-
quired sensitivity, or which testing interval that should be recommended. Also, cost is a draw-
back compared to other screening methods and stool DNA is currently not recommended in 
population based screening programs. 
 
Factors influencing the outcome of faecal screening tests 
Age 
With increasing age the uptake, i.e. the proportion of individuals completing the test, positivity 
and cancer detection rates and the positive predictive value in screening with gFOBT  
increase 103.  The positive predictive value and faecal haemoglobin concentrations increase with 
age in screening with FIT 104,105. 
Gender 
Men have a higher incidence of distal cancer and a higher risk of advanced cancer findings at 
the screening colonoscopy 106,107. Furthermore, the cancer detection and positivity rates and 
positive predictive value using gFOBT are higher in men, as are the positivity rates and the fae-
cal haemoglobin concentrations using FIT 104-108. 
The uptake, irrespective of gFOBT or FIT is higher in women, who reach the same levels of 
CRC incidence and mortality seen in men, but 4 to 8 years later 109,110. Despite this the rate of 
interval cancer, i.e. cancers that are diagnosed after a negative screening test but in the interval 
before the next scheduled test, is higher in women 108. 
Compliance  
In most population based screening programmes with FOBT the overall uptake is below 60 %, 
even though its higher with FIT than with gFOBT 109. In the randomised sigmoidoscopy trials 
the participation rates in the intervention groups ranged from 58-87 % 111.  
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In groups with low socio-economic status, the uptake in gFOBT, the uptake of colonoscopy in 
men with positive gFOBT, and furthermore the positive predictive value for cancer of gFOTB is 
reduced 103. A relationship between increasing social deprivation and higher levels of faecal 
haemoglobin concentrations has also been demonstrated using FIT 101. 
Regarding gender differences, gFOBT and FIT both detect male cancer to a higher extent than 
female. This could partly be explained by the larger proportion of more distal, thus more bleed-
ing tumours in the male population. Despite the higher uptake in women and the fact that wom-
en reach the same incidence and mortality of the disease later than men, interval cancers are 
more frequently seen in women. These differences imply that a gender based differentiation in 
population based screening programmes could be considered, using a lower FIT cut-off value 
for women and a later age-interval for screening in women. How to reach the socially deprived 
groups and to increase the overall uptakte in screening programs and furthermore deciding 
which ages to include, which screening interval is optimal and which method is the most cost-
effective are other important issues to consider henceforth. 
 
Flexible sigmoidoscopy 
Four large randomised trials have reported on the effect on CRC incidence and mortality using 
sigmoidoscopy as the primary means of screening. A multicentre randomised trial in the UK 
comparing once-only flexible sigmoidoscopy to no intervention in individuals 55-64 years of 
age, demonstrated a reduction in CRC incidence and mortality of over 30 % and 40 % respec-
tively in those who underwent screening (per-protocol analysis) 112. Almost identical results 
regarding incidence and mortality was demonstrated in the per-protocol arm in an Italian multi-
centre randomised study with a protocol similar to the UK study 113. In both trials eligible indi-
viduals prior to inclusion answered a question on whether they would accept an offer of screen-
ing. This procedure in order to increase statistical power could however also be a potential 
source of self-selection bias. An American trial used data from the multicentre Prostate, Lung, 
Colorectal and Ovarian (PLCO) Cancer Screening Trial. The colorectal cancer part of the trial 
compared no intervention to sigmoidoscopy at two occasions, 3 or 5 years apart, and demon-
strated a 21 % reduction of CRC incidence in the sigmoidoscopy group compared to the control 
group. The reduction in incidence was significant for both distal (29 %) and proximal (14 %) 
cancer. The overall 26 % reduction in CRC mortality was represented by a 50 % mortality re-
duction in patients with distal cancer, while no significant reduction in proximal cancer was 
seen compared to the control group 114. Opposite to results from the American trial no statisti-
cally significant incidence reduction could be demonstrated for cancer in in the proximal colon 
in the UK and Italian trials. Finally, a Norwegian trial comparing flexible sigmoidoscopy  
± FOBT to non-screening in 56.000 participants aged 55-64 years reported no difference in 7-
year cumulative CRC incidence between the groups. However, for those actually screened (per-
protocol group) CRC mortality was reduced by 59 % overall, and by 76 % in patients with dis-
tal cancer compared to controls 115.  In the intention-to-screen group, CRC mortality was re-
duced by 27 % overall, and by 37 % in distal cancer, but this was not statistically significant. 
One possible explanation to this, according to the authors, would be that the time from precur-
sor lesion to cancer is longer than expected, therefore not being caught by the minimum of 5-
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year mortality follow-up. However, after a 20-year follow-up in the Nottingham FOBT trial, 
with removal of hundreds of adenomas, there was no significant difference in CRC incidence 
between the intervention and control arm 116. This is interesting and not in line with the results 
from the UK, Italian and US sigmoidoscopy trials, but in concordance with the Norwegian trial 
where no difference in CRC incidence was seen between the screened and non-screened group. 
Either the adenoma-cancer pathway is not as strong as presumed or it’s the opposite: we don’t 
remove enough of adenomas to have an effect on CRC incidence. Thus, the effect on mortality, 
for those undergoing sigmoidoscopy seems unquestionable, at least for distal cancer, but the 
effect on CRC incidence and the benefit of adenoma-removal needs further evaluation. 
Optimal age of sigmoidoscopy screening 
According to a report for the British National Health System (NHS) an optimal age interval for 
sigmoidoscopy screening could be theoretically modelled. Screening at the age of 55 with sig-
moidoscopy generated the greatest gain in quality adjusted life years (QALYs), but the greatest 
reduction in CRC incidence and mortality was seen for screening with sigmoidoscopy at the age 
of 64. Screening with sigmoidoscopy at age 55 followed by biennial FIT until age 74 was con-
sidered the overall most effective strategy, taking into account the reduction in CRC incidence, 
mortality and costs 117. 
 
Colonoscopy 
Colonoscopy as a primary means of screening is widely used for example in the U.S., however 
no randomised trials have been performed comparing colonoscopy to non-intervention regard-
ing the incidence and mortality of CRC. Observational studies comparing colonoscopy to no 
intervention demonstrate a 69 % and 68 % reduction of CRC incidence and mortality respec-
tively in summary estimates from a recent meta-analysis by Brenner et al., 2014 111. 
The NordICC trial, currently recruiting, is a multicentre randomised trial, investigating the ef-
fect of colonoscopy screening on CRC incidence and mortality. Once-only colonoscopy screen-
ing with removal of all detected lesions is compared to no screening in individuals 55-64    
years 118. The Swedish SCREESCO trial is a three armed study launched in 2014 aiming to in-
clude 200.000 individuals at the age of 59-62 years; 20.000 to once-only colonoscopy , 60.000 
to faecal immunological test (FIT) (year 1 and 3) followed by colonoscopy if positive, and 
120.000 as controls. CRC incidence and mortality are the primary outcome measures 119. 
Quality indicators of colonoscopy 
Adenoma detection rate and caecal intubation rate are two important quality indicators of co-
lonoscopy, as are perforation and post polypectomy bleeding in terms of complications. Ac-
cording to the recommendations of the American Society for Gastrointestinal Endoscopy (2015) 
the performance targets in CRC screening colonoscopies are: photo-documented caecal intuba-
tion rate  ≥  95 %, adenoma detection rate  ≥ 25 %,  perforation < 1/1000, and post-polypectomy 
bleeding < 10/1000 120.   
Interval cancers are defined as cancers that are diagnosed after a negative screening test but in 
the interval before the next scheduled test. An interval cancer represents either a false negative 
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screening test or a new cancer case and reflects the sensitivity and quality of the screening test. 
There is some evidence that a high adenoma detection rate ( ≥ 20 %) of the individual endosco-
pist is correlated with a lower risk of interval cancer 121. 
 
Current screening recommendations 
Since 2003 the European Union recommends screening with FOBT in men and women aged  
50 to 74 years 122. The recommendation states that:  “The screening tests…can only be offered 
on a population basis in organised screening programmes with quality assurance at all levels, if 
good information about benefits and risks, adequate resources for screening, follow-up with 
complementary diagnostic procedures and, if necessary, treatment of those with a positive 
screening test are available.” However, within the EU the implementation of the recommenda-
tion is divergent regarding the extent of implementation, the choice of screening method and 
whether the programmes are population based or not 123. 
The Swedish Board of Health and Welfare recommends that men and women between 60 and 
74 years should be offered screening for CRC with FOBT 124. Currently only the Stock-
holm/Gotland region in Sweden offers population based biennial screening for CRC with 
gFOBT, at the age of 60-69 years. This centrally administered programme started in 2008, suc-
cessively including two birth cohorts annually, with inclusion of all cohorts by 2014. Test-kits 
are mailed to the screening individuals, including a remainder after 8 weeks in case of no return. 
Positive tests ( ≥ 1/3 test cards) are followed by a referral for colonoscopy within two weeks at 
designated centres and all data are prospectively collected in a register. Parallel to this ongoing 
screening programme the national SCREESCO study was launched in 2014, in which the 
Stockholm/Gotland region is not participating. This three-armed study compares colonoscopy 
once-only to FIT (year one and three) and to a control group. CRC incidence and mortality is 
the primary outcome measure, and the aim is to establish recommendations on how to model a 
future national population based screening program for CRC. 
In the United States, colonoscopy is widely used as a primary means of screening, however not 
in population based programmes. The American College of Gastroenterology (ACG) has cho-
sen a different CRC screening strategy compared to Europe, dividing CRC screening into pre-
vention and detection tests. Colonoscopy every 10 years beginning at the age of 50 is recom-
mended as the primary prevention test and annual FIT as the primary detection test according to 
ACG guidelines 125.  
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AIMS OF THE THESIS
 
 
Overall aim 
To individualise treatment for patients with early CRC and to contribute to the goal of offer-
ing a treatment that minimises complications, morbidity and mortality while ensuring a fully 
adequate oncological outcome.  
 
Specific aims 
Paper I 
To assess the correlation between surgical intervention, age and long term survival in patients 
undergoing surgery for stage I rectal cancer. To see whether local excision could provide long 
term survival equivalent to TME surgery in patients ≥ 80 years of age. 
Paper II 
To assess risk factors for lymph node metastases in T1 and T2 rectal cancer. 
Paper III 
To compare patients with screening and non-screening detected CRC regarding staging, 
MDT-assessment and treatment. 
Paper IV 
To assess the collected burden of complications and mortality following colonoscopy and 
surgery for adenomas and CRC in patients with a positive screening FOBT. 
  
37 
 
Deborah Saraste   
 
38 
 
     
PATIENTS AND METHODS
 
 
The Swedish Colorectal Cancer Registry (SCRCR) 
This national quality registry was started in 1995 and is prospectively and continuously col-
lecting data on all patients with adenocarcinomas of the colon and rectum, covering > 98 % 
of all CRC cases in Sweden with a demonstrated high validity 2,3,126. Rectal cancer is defined 
as an adenocarcinoma within 15 cm from the anal verge. The registry is used for national 
quality audits and research and contains detailed information on preoperative work-up, clini-
cal staging (cTNM) and the surgical procedure and postoperative complications including 5-
year follow-up of recurrence and death. Also included is the histopathology report with stag-
ing (pTNM) and information on neoadjuvant and adjuvant treatment. The SCRCR is linked 
to the Swedish Cancer Register and the Cause of Death Register. 
 
The Screening Register in the Stockholm/Gotland  
screening programme 
All data from the population based screening programme in the Stockholm-Gotland region 
are prospectively collected in a register which contains detailed information on the screening 
process and the colonoscopy procedure, including data on intra-procedure complications and 
performance quality parameters such as caecal intubation rate (with photo documentation) 
and adenoma detection. Diagnoses from the histopathological examinations of excised spec-
imen are also registered. 
 
Registers held by the Board of Health and Welfare 
The National Board of Health and Welfare is a Swedish government agency under the Minis-
try of Health and Social Affairs. The National Board of Health and Welfare is responsible for 
several registers, some of which are used in Paper I-IV: 
• The Swedish National Patient Register (NPR): The Register has been colleting 
information since the 1960s. In 1984 participation was decided mandatory and 
registration of  ICD-codes is linked to economical reimbursement systems for the 
hospitals.  
The Inpatient register (IPR): Is a part of the NPR. Since 1987 all in-patient care in 
Sweden is included and ≥ 99 % of all hospital discharges are registered in the IPR, 
which has been validated showing up to 95 % accuracy of diagnoses registered 127. 
The Outpatient Register: Is also a part of the NPR. Outpatient surgery is included 
since 1997 and since 2001 outpatient visits from both private and public health 
providers are included. 
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• The Cause of Death Register: Data is available since 1961. The cause of death is 
derived from individual death certificates. Since the frequence of autospy is only 
around 20 %, the reliability of the cause of death is depeding on how accurately the 
probable cause of death is reported. The overall accuracy of death certificates is 77 % 
and is higher in younger individuals, after rapidly progressive disease or malignant 
disease and after trauma 128,129. 
• The Cancer Register: All health care providers in Sweden are bound by law to 
report all cases of cancer to this register. 
 
Paper I 
All patients in Sweden undergoing surgery for stage I (T1-2N0M0) rectal cancer January 1, 
1995 - December 31, 2006 were included in the analysis. Relative and overall survival and 
risk factors for mortality within 5 years after surgery were calculated for the whole cohort and 
in the age groups ˂ 80 and ≥ 80 years respectively. Local recurrence rates, the use of preoper-
ative radiotherapy, comorbidity as defined by the American Society of Anaesthesiologists 
(ASA) physical status classification and age were assessed in relation to surgical intervention. 
Information of the ASA classification was obtained through a separate sample, including a 
random selection of 400 patients (equally distributed between local excision and anterior re-
section/APE surgery) from 60 hospitals in the country. The hospitals were asked to contribute 
with the ASA classification as noted in the medical records at the time of surgery. 
In order to sub-classify surgical techniques in the local excision technique group, data from 
the National Patient Registry regarding procedure codes were extracted and merged with the 
original cohort data. 
 
Paper II 
All patients in Sweden undergoing abdominal surgery for rectal cancer January 1, 2007 –  
December 31, 2010, without (neo)adjuvant treatment, and with histopathologically confirmed 
radical resections of pT1-T2 tumours were included. 
Evaluation of possible predictors of lymph node metastases included the following factors 
available in the SRCR: tumour stage, level of submucosal infiltration (sm-level), tumour dif-
ferentiation, mucinous tumour type, blood vessel and perineural infiltration, tumour location 
in the rectum (cm from anal verge), age and gender.  
 
Paper III 
The study included all individuals with a positive FOBT in the Stockholm/Gotland screening 
programme January 1, 2008 - December 31, 2012. From this cohort, those with a histopatho-
logically verified CRC were further analysed. For comparison, all patients with non-screening 
detected CRC in Sweden, diagnosed during the same period of time and matched by age, 
were included. The groups were compared regarding tumour stage, preoperative staging, 
MDT-assessment, surgical and oncological treatment. 
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Paper IV 
All patients in the Stockholm/Gotland screening programme, with one positive FOBT fol-
lowed by a colonoscopy performed January 1, 2008 until June 30, 2012 were included.The 
30-day mortality and complications, defined as events requiring over-night hospital care 
within 30 days after colonoscopy or surgery for adenomas or CRC, were analysed and all 
adverse events deviating from a normal postoperative course were registered after revision of 
hospital charts. In patients with multiple complications, the most severe one was registered 
according to the Clavien-Dindo classification of surgical complications 130. 
 
Statistical analyses paper I-IV 
Paper I 
Kaplan-Meier estimates were used to calculate 5-year overall survival rates. Relative survival 
was calculated using the Hakulinen method. Hazard ratios (HR) for death were calculated 
using Cox proportional hazards regression model. Mann-Whitney U test and Chi2 test were 
used to compare the distribution of ASA classes between two groups of surgical interven-
tions. Kruskal-Wallis test was used for comparison of median ages between different groups 
of surgical interventions. P-values < 0.05 were considered statistically significant. 
Paper II 
The risk of lymph node metastases, expressed as odds ratios (OR), was calculated using uni- 
and multivariate logistic regression analyses. 
An index for predicting the risk of lymph node metastases was constructed including varia-
bles with a statistically significant risk for lymph node metastases according to the multivari-
ate logistic regression analyses. The predicted probability estimating the aggregated risk of 
lymph node metastases was based on the intercept and estimate of the multivariate analyses.  
Paper III and IV 
Pearson Chi2 test and Fisher’s exact test were used to determine significant differences in 
proportions. P-values < 0.05 were considered statistically significant. 
Statistical analyses were performed using the Statistica Release 8 (Statsoft, Tulsa, USA) and 
Stata 12.0 (StataCorp, 4905 Lakeway Drive, Collage Station, Texas 77845, USA). 
 
Ethical permission 
 
All studies were approved by the Regional Ethical Review Board in Stockholm. 
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RESULTS 
 
 
Paper I 
 
A total of 3964 patients underwent surgery for stage I rectal cancer. Table 6 shows the distri-
bution of surgical interventions, preoperative radiotherapy and 5-year local recurrence rates. 
 
Table 6. Surgical interventions, preoperative radiotherapy and local recurrence rates in patients undergoing 
surgery for stage I rectal cancer. 
 Type of sur-
gery  
(n) 
Preoperative 
Radiotherapy 
(%) 
Local recur-
rence (%) 
Anterior resection 1947 (52%) 48 2.2 
Abdominoperineal 
Resection 
982   (27%) 68 3.5 
Hartmann’s procedure 235     (7%) 35 7.2 
Local excision 448   (12%) 2 11.2 
Unspecified type of surgery, n= 64, excluded 
 
A poor survival was demonstrated in patients undergoing local excision and Hartmann’s pro-
cedure compared to patients undergoing AR or APR. In the age group ≥ 80 years this differ-
ence was even more pronounced as shown in table 7. 
 
Table 7. Total and relative 5-year survival rates after surgery for stage I rectal cancer. 
 Total  
Survival 
All Ages 
95 % CI Relative 
Survival 
<80 y 
95 % CI Relative  
Survival 
≥80 y 
95 % CI 
AR 0.80 (0.82-0.78) 0.94 (0.92-0.96) 0.99 (0.88-1.09) 
APE 0.75 (0.72-0.77) 0.88 (0.85-0.92) 0.95 (0.80-1.10) 
Hartmann’s 
Procedure 
0.57 (0.50-0.63) 0.72 (0.62-0.82) 0.91 (0.71-1.12) 
Local excision 0.62 (0.57-0.66) 0.84 (0.77-0.90) 0.74 (0.59-0.89) 
AR (anterior resection), APE (abdominoperineal excision). 
 
The median age was 5 years higher in patients undergoing local excision compared to those 
undergoing anterior resection (p< 0.001). In patients ≥ 80 years the corresponding difference 
was 2 years (p< 0.001). The ASA classification of physical status was higher in the local ex-
cision group compared to the AR/APE group (p< 0.005). 
 
Statistically significant risk factors for mortality within five years after surgery as seen in the 
multivariate analysis were: APE, HR= 1.22 (1.03-1.45), Hartmann’s procedure, HR= 1.61 
(1.28-2.02), local excision, HR= 1.58 (1.30-1.91), increasing age HR= 1.06 (1.06-1.07), male 
gender 1.70 (1.48-1.95).   
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Among patients ≥ 80 years of age local excision HR= 1.55 (1.17-2.05), male gender  
HR= 1.59 (1.27-1.99) and age HR= 1.07 (1.04-1.11) were statistically significant risk factors 
for mortality.  
 
In the local excision group further sub-division of the surgical procedures was possible in 363 
patients: TEMS n= 98 (22 %), transanal excision, n= 210 (47 %) and endoscopic resection, 
n= 55 (12 %). Multivariate analysis with sub-division of the local excision group showed the 
following hazard ratios for mortality within 5 years after surgery: endoscopic resection,  
HR= 1.79 (1.17-2.74), TEM, HR= 1.69 (1.20-2.37), transanal excision, HR= 1.62 (1.27-2.09), 
missing data 1.17 (0.76-1.81). 
 
Paper II 
 
In paper II, 205 patients with T1 and 472 patients with T2 disease were identified, and the 
overall proportion of patients with lymph node metastases were 12 % and 22 % in patients 
with T1 and T2 tumours respectively. 
The multivariate logistic regression analyses identified the following risk factors for lymph 
node metastases: T2 tumour stage, OR= 1.97 (1.19-3.25), poor differentiation, OR= 6.47  
(2.71-15.4), vascular infiltration, OR= 4.34 (2.46-7.65). 
Stratification of risk depending on the number of risk factors added is shown in figure 2. The 
risk index shown here is a revised and corrected version of the index published in paper II. 
The revision of does not affect the risk of lymph node metastases. 
 
Figure 2. Risk of lymph node metastases in T1 and T2 tumours.  
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Paper III 
 
Among the nearly 206.000 individuals receiving a test kit, compliance was 64 %. The posi-
tivity rate (positive FOBT/ performed tests) was 3.5 % and the positive predictive value of 
colonoscopy, i.e. histopathologically confirmed CRC in patients undergoing colonoscopy 
after a positive FOBT was 6 %. Staging of the primary tumour and metastases, and MDT 
assessments were more complete in patients with screening detected cancer compared to 
those with non-screening detected cancer (p< 0.0001). Within both groups, among patients 
with endoscopically resected cancer, staging and preoperative MDT assessment was less 
complete than among patients with surgically resected cancer (p < 0.001). 
A higher proportion of stage I disease, 41 % vs.15 % (pTNM) (p< 0.001), a larger proportion 
of colon cancer, 72 % vs. 62 % (p< 0.05) and fewer acute interventions 2 % vs.12 %  
(p< 0.001) were seen in the screening, compared to the non-screening group. 
Of patients undergoing elective surgical resection, 99.5 % and 99 % in the screening and non-
screening group respectively underwent abdominal resection surgery (Fig 3). 
In patients electively treated for rectal cancer in (cTNM) stage I disease, there was no differ-
ence between the screening and non-screening groups regarding the use of local excision 
techniques (p= 1.0). In the screening group 23 % of patients had stage I disease and 6 % of 
these were treated with local excision. The corresponding numbers in the non-screening 
group were 6 % stage I disease and 9 % treated with local excision. 
Neoadjuvant (C)RT was given to 68 % and 76 % of patients with rectal cancer in the screen-
ing and non-screening groups respectively (p= 0.14). Regarding adjuvant chemotherapy in 
(pTNM) stage II and III, no statistically significant difference was seen between the groups 
(p= 0.15). 
 
Figure 3. Treatment in patients with screening and non-screening detected CRC. 
* Excluded, n= 37:  unspecified operation (n= 16), appendectomy (n= 9), missing (n= 12) 
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Paper IV 
 
Subsequent to a positive gFOBT in the screening programme 2984 individuals underwent a 
colonoscopy. Of these, 37 and 155 patients underwent surgery for adenomas and CRC re-
spectively. After colonoscopy the incidence of post-polypectomy bleeding was 14/1000. Per-
foration occurred in 1/1000 after diagnostic procedures and 2.5 /1000 after therapeutic proce-
dures. Post-polypectomy syndrome occurred in one patient. The total complication rate after 
colonoscopy was 1 %. One patient died within 30 days after colonoscopy, but without rela-
tion to the colonoscopy-procedure. In the adenoma surgery group the complication rate was 
27 % and the rate of anastomotic leakage was 13 %. In the cancer surgery group complication 
and anastomotic leakage rates were 50 % and 12 % respectively. There was no 30-day mor-
tality after surgery for adenomas or cancer. No statistically significant correlation regarding 
complications was seen in relation to tumour stage (p= 0.8), or when comparing prevalent 
and incident screening rounds (p= 0.4). 
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DISCUSSION
 
 
Screening for colorectal cancer 
Screening for CRC enables detection and removal of precursor lesions, i.e. adenomas, and 
detection of cancer at an early stage, which is the key to reducing CRC mortality, since sur-
vival in CRC is dependent on tumour stage. In randomized trials using gFOBT, a 16 % reduc-
tion in CRC mortality has been demonstrated, and also detection of cancer at an earlier stage 
in screening compared to control groups 131. Later RCTs assessing screening sigmoidoscopy 
have demonstrated an incidence reduction in distal CRC of 31 % and 42 % in the intention to 
screen and per protocol analysis respectively, with corresponding numbers of 41 % and 61 % 
in the reduction of distal CRC mortality 111. 
In paper III follow-up time did not allow for assessment of long term survival, but in line 
with the randomized trials assessing gFOBT, screening detected cancer was found at an earli-
er stage, both cTNM and pTNM stage, compared to non-screening detected cancer. Emer-
gency interventions were fewer in the screening compared to the non-screening group  
(2 % vs.12 %), which is likely to impact survival since previous studies have demonstrated 
that emergency intervention is a risk factor for increased short term mortality and reduced 
long term survival 132. 
However for a screening programme to be efficient, not only reduction in CRC mortality is 
needed but also adherence to the programme. In paper III uptake with gFOBT was 64 %, 
which is high compared to other studies and considering that compliance is generally lower 
with gFOBT compared to FIT. For example the Scottish screening programme demonstrated 
an uptake of 54 % with gFOBT and 59 % with FIT 109.  In paper III, 88 % of individuals with 
a positive FOBT underwent the recommended colonoscopy indicating that individuals partic-
ipating in the programme are motivated to complete investigations following a positive test 
result. In the UK and Italian sigmoidoscopy trials compliance was 71 % and 58 % respective-
ly, however inclusion was made from individuals indicating an interest to attend screening, 
thereby inducing possible self-selection bias 112,113. The Norwegian sigmoidoscopy trial was 
population based, reporting an attendance rate to sigmoidoscopy of 65 %  indicating that high 
compliance could be achieved to an invasive procedure without previous selection of partici-
pants 115. How compliance would be in a fully expanded population based program using 
sigmoidoscopy or colonoscopy outside a trial situation is not known. 
Complications and overtreatment are two other important issues of screening programmes. 
Complications after colonoscopies and cancer surgery are well documented, but very few 
studies have tried to assess the collected burden of complications that arise as a result of a 
positive FOBT. In paper IV, complications after colonoscopy, surgery for adenomas and sur-
gery for CRC were evaluated. Total complication rates of 27 % and 50 % after adenoma and 
CRC surgery respectively were demonstrated. The rates of anastomotic leakage were 13 % 
and 12 % in the adenoma and CRC surgery groups respectively. The rates of post-
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polypectomy bleeding and perforation were 14/1000 and 2.5/1000 respectively, reported per 
patient and not per polypectomy. Compared to a previous study by Kewenter et al. assessing 
the collected complications after screening-induced interventions in the randomized Gothen-
burg FOBT-trial in the 90s, the complication rates presented in paper IV are high. Kewenter 
et al. reported a total complication rate of 13 % after surgery for CRC and benign findings 133. 
However, many present studies report total complication rates of 50 % after CRC surgery, but 
usually lower rates of anastomotic leakage than those presented in paper III are  
reported 38,42,134. The reasons for this could be that the definition of anastomotic leakage is not 
uniform, and that reporting, validity of reported data, and the possibility of scrutinizing medi-
cal charts may vary. Robinson et al. reporting from the Nottingham randomized trial on 
gFOBT screening reported a perforation rate of 3/1000, and the study by Kewenter et al. pre-
sented a post-polypectomy perforation rate of 8/1000 which is higher than in paper IV 133,135 . 
Reduction of mortality in CRC is the primary outcome measure when evaluating screening 
and such a precise measure is difficult to implement when assessing the impact of overall 
complications generated by screening. This makes it hard to compare net effects in terms of 
mortality reduction contra risks as long as the magnitude of the complications doesn’t coun-
terbalance the mortality reduction in CRC. Putting the results of paper IV in relation to other 
studies and quality guidelines, the complication rates in paper IV are judged to be within ac-
ceptable limits. 
The idea of the adenoma-carcinoma pathway is generally accepted and hence removal of 
screening detected adenomas is adequate in order to reduce CRC incidence and  
mortality 93,94. However, not all precursor lesions will transform into malignant lesions. Re-
moval of adenomas with low grade dysplasia, where colonoscopy or subsequent surgery 
leads to complications is a problem of overtreatment. In paper IV, the total number of com-
plications after adenoma surgery was small, as was the number of patients undergoing sur-
gery for adenomas. Thus on a cohort level, overtreatment of adenomas is not a problem, but 
for the individual patient and surgeon complications after “unnecessary” surgery are prob-
lematic. 
In paper III, there were no statistically significant differences between the screening and non-
screening groups regarding the extent of surgical or oncological treatment, hence neither 
over-, nor under-treatment could be detected in the screening compared to the non-screening 
group. 
The implementation of population based screening programmes for CRC will generate a 
higher proportion of early stage cancer. Consequently, for these patients with early stage can-
cer, treatment options minimising morbidity are of importance. In this perspective local exci-
sion techniques and non-surgical treatment will come in to focus. 
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Early rectal cancer 
The different treatment options in early rectal cancer have gained more attention than those of 
early colon cancer. This is due to anatomical differences between the colon and rectum, 
which will impact treatment and results. The envelope of the mesorectum allows for full 
thickness local excision techniques of early tumours below the peritoneal reflection. This is 
not possible in the colon where a corresponding procedure would lead to a perforation into 
the abdominal cavity. Furthermore, the functional consequences of an AR or APE compared 
to organ sparing techniques in the rectum are apparent, whereas the corresponding functional 
disadvantages of open surgery compared to minimally invasive techniques in colon surgery 
are less pronounced. 
The TME–technique has set a reference point for survival and local recurrence rates in rectal 
cancer. However, regarding morbidity, mortality, functional outcome, organ preservation and 
patient preference in early rectal cancer treatment possibilities other than AR or APE, i.e. 
local excision techniques are of interest. Initially, transanal excision was the only alternative 
in local excision of rectal cancer, but with technical advances TEMS is now the surgical 
method of choice. In endoscopy, the ESD technique allows for en-bloc resections of larger 
lesions than previously. Furthermore the prospect of complete response after neoadjuvant 
CRT has emerged as yet another alternative in the treatment of early rectal cancer. 
However, all techniques of local excision face the same central dilemma regarding lymph 
nodes: radiology cannot (yet) predict the presence of lymph node metastases with a specifici-
ty of more than around 70 % and local excision techniques cannot remove the mesentery and 
possible lymph node metastases 6. The non-resected nodes account for the problem of high 
local recurrence rates after local excision surgery. To some extent also non-radical resections 
contribute to higher local recurrence rates, especially using transanal excision, but with the 
introduction of TEMS, non-radical resections are no longer a major issue 63,89. 
One way of dealing with the problem is to consider local excision with TEMS as a ”macro-
biopsy”. If  histopathology would reveal the presence of adverse features increasing the risk 
of lymph node metastases, additional treatment with AR or APE would be recommended. In 
paper II, risk factors for lymph node metastases were assessed, demonstrating T2 stage, poor 
differentiation and vascular infiltration as statistically significant risk factors for lymph node 
metastases. These factors are also identified by other studies along with a number of other 
risk factors such as tumour depth of invasion, lymphatic invasion and tumour budding 71,72 .  
Since long the correlation between intramural invasion and an increasing risk of lymph node 
metastases has been demonstrated 66,67. However, as demonstrated in paper II, not only stage, 
but the combination of different risk factors determines the overall risk of lymph node metas-
tases. In paper II, the risk ranges from 6-65 % in T tumours and from 11-78 % in T2 tumours. 
Thus, a low-risk T2 tumour could have a smaller risk of lymph node metastases than a high-
risk T1 tumour. However general recommendations of using local excision for only T1sm1 
tumours is not taking into account the differentiation of risk depending on the number of add-
ed risk factors 78. Different studies have constructed other risk stratification models but these 
are all theoretical models and how to implement the results in clinical practice needs further 
discussion 68,136,137. If using a large population based material not flawed by missing data, 
based on meticulous histopathological examinations and with future possible biomarkers in-
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cluded, a validated, clinically relevant risk index assessing the risk of lymph node metastases 
after local excision should be possible to construct. 
Regarding the issue of salvage surgery, i.e. abdominal resection surgery in case of local re-
currence after local excision of rectal cancer, studies have demonstrated 3 and 5-year survival 
rates of 53-58% and distant metastases in 16-39 % of cases 138,139 . However, in immediate 
salvage surgery, meaning abdominal resection surgery within a month after TEMS where 
histopathology has revealed adverse features, long term survival have been reported as equal 
to that after primary TME surgery 140. The procedure of immediate salvage surgery is current-
ly recommended in case of adverse features after local excision of rectal cancer, according to 
the European Society for Medical Oncology Guidelines for management of rectal cancer 78. 
In paper I a local recurrence rate of 11.2 % was seen after local excision compared to rates of 
2.2 % and 3.5 % after AR and APE respectively. Furthermore, 5-year relative survival after 
local excision (81 %) was poor in all ages compared to AR (95 %) and APR (89 %), and this 
difference was even more pronounced in patients  ≥ 80 years. In concordance with our find-
ings in paper I, numerous trials have demonstrated higher local recurrence rates after local 
excision compared to TME surgery whereas, opposite to the findings in paper I, no difference 
in long term survival has been demonstrated 63. In paper I, the poor survival found in patients 
undergoing local excision could be due to a selection of old patients with a high comorbidity. 
The local excision group was further sub-classified to assess 5-year relative survival of pa-
tients undergoing resection with TEMS, transanal excision or endoscopic resection. The re-
sults were not in favour of the TEMS (75 %) group compared to patients undergoing 
transanal (82 %) or endoscopic resection (76 %). From available data, the reasons for this are 
not clear. 
Included in the term local excision are endoscopic resections. Due to several reasons endo-
scopic resections cannot however presently be regarded as a fully equivalent alternative to 
TEMS in case of rectal cancer. The knowledge of how to use the ESD technique for resection 
of rectal lesions is still developing. Even if so called en-bloc resection rates, i.e. resection of 
the tumour in one piece, are higher than with traditional endoscopic resection techniques us-
ing piecemeal resection, en-bloc resection are performed in 90-97 %, and complete R0 resec-
tions only in 80-97 % of cases 61,141 . Furthermore, the issue of lymph node metastases re-
mains the same as in other local excision techniques. No large studies regarding long-term 
oncological outcome after resection of early rectal cancer comparing ESD to TME surgery 
have been performed. Finally, as demonstrated in paper III the preoperative staging and 
MDT-assessment of patients with endoscopically resected, both screening detected and non-
screening detected CRC is performed to a smaller extent than in the surgical resection groups. 
This is also an indication that endoscopy has not yet founds its place as a fully adequate op-
tion for resection of CRC. 
In recent years a lot of interest has arisen around organ preservation and complete response 
after neoadjuvant therapy with or without additional surgery in case of early rectal cancer. 
The CRT regimen used in many of the trials assessing complete response is equivalent to the 
long-course CRT advocated for downstaging of advanced rectal cancer 78,87-90. This way of 
using the most intense CRT for early rectal cancer is not in line with traditional reasoning 
around benefits and side effects of neoadjuvant therapy, at least not in how it has been re-
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flected in guidelines for early rectal cancer, where recommendations are to proceed to surgery 
without previous neoadjuvant therapy. In case of success, i.e. complete clinical response, the 
goal of organ preservation is achieved, and the cost for the individual patient in terms of neg-
ative side effects is probably acceptable. However, in case of no response; a situation requir-
ing additional AR or APE, the patient will not only have the side effects of pelvic surgery 
itself, but also of heavy CRT.  
By combining (C)RT and TEMS the risk of leaving of remaining lymph node metastases 
decreases due to the neoadjuvant therapy, even if the central problem with the local excision 
technique and lymph nodes remains. However, if subsequent abdominal resection surgery is 
needed in case of local failure, the patient will, as in the case of incomplete response, encoun-
ter the negative side effects of both CRT and pelvic surgery. In addition, the abdominal resec-
tion surgery can be more complicated due to scarring after TEMS. 
Looking at time trends in the use of local excision in stage I rectal cancer in Sweden no in-
crease is seen over time. In paper I, 12 % of patients with stage I rectal cancer underwent 
surgical treatment with local excision in 1995-2006, compared to 9 %, 2007-2010 (paper III). 
The difference when comparing with the US where 55 % of stage I rectal cancer was treated 
with local excision in 2010, is interesting. The underlying causes for these differences are not 
clear 64. 
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FUTURE PERSPECTIVES
 
 
Further expansion of population based screening for CRC will generate a need of follow-up 
after screening detected cancer and adenomas. How to allocate nationally equal resources for 
the consequent need of colonoscopy, even in screening programmes using FOBT, could be-
come a challenge. There is also an interesting issue of compliance when multiple screening 
programmes are running in a population. A woman in living in Sweden today is invited to 
attend screening programs for breast cancer, cervical cancer and (if living in the Stockholm-
region) colorectal cancer. How will individual compliance be affected by participation in 
multiple non-synchronised screening programs? 
 
With coming generations of well-informed CRC patients and patient-organisations, the de-
mand for surgical interventions with a low morbidity combined with good functional and 
aesthetical results in early CRC is likely to increase. The increasing awareness within the 
surgical society on the issue of function and quality of life after surgery, in combination with 
the surgical interest in minimally invasive techniques will continue to drive the development 
and utilisation of laparoscopic, robotic and endoscopic surgery. Currently experimental tech-
niques such as transanal total mesorectal excision and combined endoscopic/laparoscopic 
procedures will probably be developed and further integrated as possible treatment options 
62,142. Furthermore, radiological advances increasing the accuracy in predicting lymph node 
metastases would facilitate the selection of patients with tumours suitable for local excision 
techniques.  
 
The issue of complete tumour response after neoadjuvant therapy has created the possibility 
of a non-surgical treatment with a curative intent. Also the combination of different neoadju-
vant treatment modalities and local excision, i.e. TEMS, is gaining attention, with interesting 
results from ongoing trials to be awaited. 
The idea of heavy chemoradiotherapy in early rectal cancer is challenging, since it puts aside 
the current perception of the risk-benefit ratio of neoadjuvant therapy in early stage disease. 
The aim of individualised treatment minimising the negative effects of surgery must not 
come at the price of non-surgical overtreatment. 
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CONCLUSIONS
 
 
• Patients treated with local excision in stage I rectal cancer had a poor 5–year survival 
compared to patients undergoing surgery with anterior resection or abdominoperineal 
excision. This difference was even more pronounced in patents ≥ 80 years of age. 
There could be a selection of old patients with high comorbidity to surgery with local 
excision. 
 
• T2 stage, poor differentiation and vascular infiltration were risk factors for lymph 
node metastases in rectal cancer. There was a differentiation of risk depending on the 
presence of different risk factors, creating a large span between high and low risk T1 
and T2 tumours respectively. 
 
• Staging and MDT-assessments were more frequently performed in patients with 
screening detected cancer compared those with non-screening detected cancer. The 
surgical and oncological treatment did not differ between the groups. Patients with 
endoscopically resected cancer were not staged and MDT-assessed to the same extent 
as were those with surgically resected cancer, and in this respect, no difference was 
seen between the screening and non-screening group. 
 
• After interventions following a positive screening FOBT, overall complication rates 
were acceptable and mortality low after colonoscopy and surgery for adenomas and 
cancer. However, the rates of anastomotic leakage were higher than expected after 
surgery.  
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